BioSpace News Archive

Mainz Biomed NV, a leading molecular genetics diagnostic company focused on early cancer detection, announced its participation in the upcoming UEG Week.

Apnimed, Inc. announced today the company will be participating in the following investor conferences in October 2023.

Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform, announced it will report financial results for the third quarter before market open on Tuesday, October 31, 2023.

PDS Biotechnology Corporation announced interim safety and immune response data for the first-in-human Phase 1/2 clinical trial evaluating PDS0301, a novel investigational tumor-targeting, antibody-conjugated Interleukin 12, in combination with current standard-of-care chemotherapy, docetaxel, to treat metastatic castration sensitive and castration resistant prostate cancer.

Tempest Therapeutics, Inc. announced that its Board of Directors has adopted a limited duration stockholder rights plan, effective immediately.

Assembly Biosciences, Inc. announced that preclinical and clinical data from its virology portfolio will be featured in two presentations at the upcoming American Association for the Study of Liver Diseases, The Liver Meeting®, taking place November 10-14, 2023, in Boston.

Bionano Genomics, Inc. announced the pricing of $45.0 million aggregate principal amount of senior secured convertible notes due 2025 and warrants to purchase 21,660,650 shares of its common stock in a registered offering, and $35.0 million aggregate principal amount of senior secured convertible notes due 2025 in a concurrent private placement, in each case, to a certain accredited investor.

Tempest Therapeutics, Inc. announced new and updated positive results from the planned data analysis of an ongoing global randomized Phase 1b/2 clinical study in which TPST-1120, Tempest’s PPAR⍺ antagonist, shows clinical superiority in multiple study endpoints when combined with atezolizumab and bevacizumab in a randomized comparison to atezolizumab and bevacizumab in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma.

Bionano Genomics, Inc. reported certain business updates and unaudited preliminary financial results for the third quarter ended September 30, 2023.

Boehringer Ingelheim Ltd. and BI X, the digital lab of Boehringer Ingelheim, have collaborated to introduce a new digital clinical support tool for Canadian healthcare professionals managing the care of individuals with type 2 diabetes mellitus.